Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer

Table 1 Patient characteristics

	XP (n = 77)	SP (n = 97)	DP (n = 72)	FP (n = 37)
Age, years
Median	59	53	51	60
Range	35-77	33-75	28-78	30-75
Gender
Male	55	63	41	20
Female	22	34	31	17
ECOG performance status
0	17	15	10	4
1	56	70	51	27
2	4	12	11	6
Prior therapy
Curative resection	11	22	33	7
Palliative gastrectomy	24	27	16	16
Adjuvant therapy	6	18	31	8
Involved sites(s)
Abdominal lymph nodes	55	64	39	12
Liver	23	25	16	8
Lung	3	7	3	3
Peritoneum	41	45	39	28
Bone	3	8	9	1
Ovary	4	7	3	1

XP; capecitabine + cisplatin; SP, S-1 + cisplatin; DP, docetaxel + cisplatin; FP, 5-fluorouracil + cisplatin; ECOG, Eastern Cooperative Oncology Group.

ISSN: 1471-2407